CrystalGenomics Inc (083790) - Total Liabilities

Latest as of September 2025: ₩124.24 Billion KRW ≈ $84.20 Million USD

Based on the latest financial reports, CrystalGenomics Inc (083790) has total liabilities worth ₩124.24 Billion KRW (≈ $84.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CrystalGenomics Inc (083790) equity growth momentum to track the company's year-over-year net asset growth rate.

CrystalGenomics Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how CrystalGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. See 083790 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

CrystalGenomics Inc Competitors by Total Liabilities

The table below lists competitors of CrystalGenomics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Efficient E Solutions Bhd KLSE:0064	Malaysia	RM11.79 Million
YSX Tech. Co., Ltd Class A Ordinary Shares NASDAQ:YSXT	USA	$16.96 Million
Neuphoria Therapeutics Inc NASDAQ:NEUP	USA	$6.90 Million
STS Group AG XETRA:SF3	Germany	€177.70 Million
Spacenet Enterprises India Limited NSE:SPCENET	India	Rs496.11 Million
ClearSign Combustion Corporation NASDAQ:CLIR	USA	$2.65 Million
Shenzhen Shenbao Industrial Co Ltd SHE:200019	China	HK$2.43 Billion
Nano Chem Tech Inc KQ:091970	Korea	₩49.56 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down CrystalGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 083790 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.45	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.82	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.59	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CrystalGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CrystalGenomics Inc (2011–2024)

The table below shows the annual total liabilities of CrystalGenomics Inc from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩161.95 Billion ≈ $109.75 Million	+65.55%
2023-12-31	₩97.82 Billion ≈ $66.29 Million	-27.18%
2022-12-31	₩134.34 Billion ≈ $91.04 Million	+7.39%
2021-12-31	₩125.09 Billion ≈ $84.77 Million	+22.39%
2020-12-31	₩102.20 Billion ≈ $69.26 Million	-55.59%
2019-12-31	₩230.14 Billion ≈ $155.96 Million	+217.64%
2018-12-31	₩72.45 Billion ≈ $49.10 Million	+159.89%
2017-12-31	₩27.88 Billion ≈ $18.89 Million	-38.74%
2016-12-31	₩45.51 Billion ≈ $30.84 Million	-17.77%
2015-12-31	₩55.34 Billion ≈ $37.51 Million	+8.47%
2014-12-31	₩51.02 Billion ≈ $34.58 Million	-3.01%
2013-12-31	₩52.61 Billion ≈ $35.65 Million	+62.91%
2012-12-31	₩32.29 Billion ≈ $21.88 Million	-0.92%
2011-12-31	₩32.59 Billion ≈ $22.09 Million	--

About CrystalGenomics Inc

KQ:083790 Korea Pharmaceuticals

Market Cap

$20.89 Million

₩30.82 Billion KRW

Market Cap Rank

#24917 Global

#1791 in Korea

Share Price

₩762.00

Change (1 day)

+2.42%

52-Week Range

₩744.00 - ₩1887.00

All Time High

₩18365.04